This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Hyperprolactinemia

Menopause

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Monitoring and Management

Dose Adjustment

To optimize outcomes for patients who begin dopamine agonist therapy, routine follow-up of prolactin is imperative for guiding dose adjustment.1

Serum prolactin should be measured 1 month after initiating dopamine agonist therapy and routinely repeated, as necessary.1,2

Other Assessments

Aside from monitoring prolactin levels and adjusting dopamine agonist therapy to achieve prolactin normalisation, other follow-up assessments should be conducted during treatment.1

Treatment Discontinuation

Dopamine agonists should be given continuously for at least 2 years. After this time, therapy can be tapered and perhaps even discontinued if prolactin levels have remained at normal levels for 2 years and there is no visible tumor remaining on MRI.1
If treatment tapering/discontinuation is pursued, careful follow-up is required to monitor for recurrence.1


Dostinex (cabergoline) prescribing information can be found here

​​​​​​​
References
1.Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
2.Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, Ollero García-Agulló D; Grupo de Trabajo de Neuroendocrinología de la SEEN. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinol Nutr. 2013;60(6):308-319.
​​​​​​​

PP-UNP-GBR-0580. June 2022

What is Hyperprolactinaemia?

See general information including pathophysiology and etiology
​​​​​​​

Learn more

Identifying Common Symptoms

Understand what signs to look for and explore two patient case studies
​​​​​​​

Learn more

Interpreting Test Results

Recognise which tests to order and what the results indicate
​​​​​​​​​​​​​​

Learn more

Selecting Treatment based on Guidelines

Determine therapy based on clinical and patient factors
​​​​​​​​​​​​​​

Learn more

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?